Used in pharmaceutical research as a potent inhibitor of cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6. It is investigated for its antitumor activity, especially in cancers driven by dysregulation of the cell cycle, such as breast cancer and melanoma. The compound shows promise in blocking the progression of cancer cells from the G1 to the S phase of the cell cycle, leading to cell cycle arrest and apoptosis. Due to its targeted mechanism, it is being studied in the development of selective kinase inhibitors with improved efficacy and reduced side effects compared to traditional chemotherapy.